Journey Medical Corporation (DERM)
USD 6.21
(2.99%)
USD 6.21
(2.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.85 Million USD | 87.0% |
| 2022 | -29.62 Million USD | 32.65% |
| 2021 | -43.99 Million USD | -932.75% |
| 2020 | 5.28 Million USD | 45.74% |
| 2019 | 3.62 Million USD | 101.64% |
| 2018 | -221.54 Million USD | 26.95% |
| 2017 | -303.26 Million USD | -240.42% |
| 2016 | -89.08 Million USD | -13.63% |
| 2015 | -78.39 Million USD | -145.96% |
| 2014 | -31.87 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -3.36 Million USD | 67.81% |
| 2024 Q1 | -10.44 Million USD | -387.26% |
| 2023 FY | -3.85 Million USD | 87.0% |
| 2023 Q3 | 16.78 Million USD | 300.75% |
| 2023 Q4 | -2.14 Million USD | -112.76% |
| 2023 Q1 | -10.06 Million USD | 5.46% |
| 2023 Q2 | -8.36 Million USD | 16.88% |
| 2022 Q2 | -7.52 Million USD | -446.3% |
| 2022 FY | -29.62 Million USD | 32.65% |
| 2022 Q1 | -1.37 Million USD | 93.66% |
| 2022 Q4 | -10.64 Million USD | -5.58% |
| 2022 Q3 | -10.08 Million USD | -33.9% |
| 2021 Q2 | -11.86 Million USD | -4527.24% |
| 2021 Q3 | -10.64 Million USD | 10.27% |
| 2021 Q4 | -21.75 Million USD | -104.31% |
| 2021 FY | -43.99 Million USD | -932.75% |
| 2021 Q1 | 268 Thousand USD | -89.29% |
| 2020 Q3 | 29 Thousand USD | -93.63% |
| 2020 FY | 5.28 Million USD | 45.74% |
| 2020 Q2 | 455 Thousand USD | -66.93% |
| 2020 Q4 | 2.5 Million USD | 8527.59% |
| 2020 Q1 | 1.37 Million USD | 0.0% |
| 2019 Q1 | -64.83 Million USD | 9.72% |
| 2019 FY | 3.62 Million USD | 101.64% |
| 2019 Q3 | -57.62 Million USD | -220.79% |
| 2019 Q2 | -17.96 Million USD | 72.29% |
| 2018 Q2 | -23.93 Million USD | 59.61% |
| 2018 Q3 | -66.54 Million USD | -178.05% |
| 2018 Q4 | -71.81 Million USD | -7.91% |
| 2018 FY | -221.54 Million USD | 26.95% |
| 2018 Q1 | -59.25 Million USD | -5.79% |
| 2017 Q1 | -29.5 Million USD | -299.69% |
| 2017 FY | -303.26 Million USD | -240.42% |
| 2017 Q4 | -56.01 Million USD | 68.74% |
| 2017 Q3 | -179.17 Million USD | -364.59% |
| 2017 Q2 | -38.56 Million USD | -30.69% |
| 2016 Q4 | -7.38 Million USD | 71.06% |
| 2016 Q3 | -25.51 Million USD | 54.6% |
| 2016 FY | -89.08 Million USD | -13.63% |
| 2016 Q2 | -56.19 Million USD | -97.61% |
| 2016 Q1 | -28.43 Million USD | 63.73% |
| 2015 Q1 | -14.03 Million USD | -108.64% |
| 2015 Q2 | -31.19 Million USD | -122.26% |
| 2015 Q3 | -16.05 Million USD | 48.53% |
| 2015 FY | -78.39 Million USD | -145.96% |
| 2015 Q4 | -78.39 Million USD | -388.35% |
| 2014 Q4 | -6.72 Million USD | 0.0% |
| 2014 FY | -31.87 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 108.001% |
| Embecta Corp. | 70.4 Million USD | 105.473% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 120.518% |
| Dynavax Technologies Corporation | -6.38 Million USD | 39.693% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 98.159% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 109.184% |
| PainReform Ltd. | -9.34 Million USD | 58.765% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 51.042% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 14.493% |
| SCYNEXIS, Inc. | 67.04 Million USD | 105.747% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -24.349% |
| Cosmos Health Inc. | -18.54 Million USD | 79.221% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 14.493% |
| Safety Shot Inc | -15.08 Million USD | 74.455% |
| Alpha Teknova, Inc. | -36.78 Million USD | 89.524% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 97.241% |
| Bright Green Corporation | -13.12 Million USD | 70.65% |
| Procaps Group, S.A. | 42.54 Million USD | 109.057% |
| Theratechnologies Inc. | -23.95 Million USD | 83.917% |
| Harrow Health, Inc. | -24.41 Million USD | 84.216% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 20.31% |
| Biofrontera Inc. | -20.13 Million USD | 80.86% |
| DURECT Corporation | -27.62 Million USD | 86.052% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 392.781% |
| Cronos Group Inc. | -73.96 Million USD | 94.791% |
| OptiNose, Inc. | -35.48 Million USD | 89.141% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 99.616% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 90.869% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 116.111% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 177.917% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 2538.098% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 38.64% |
| Radius Health, Inc. | -25.79 Million USD | 85.061% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 37.482% |
| ProPhase Labs, Inc. | -16.78 Million USD | 77.041% |
| Phibro Animal Health Corporation | 2.41 Million USD | 259.478% |
| Procaps Group S.A. | 42.54 Million USD | 109.057% |
| Alvotech | -551.73 Million USD | 99.302% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 62.512% |
| Viatris Inc. | 54.7 Million USD | 107.044% |
| Rockwell Medical, Inc. | -8.43 Million USD | 54.343% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 75.682% |
| SIGA Technologies, Inc. | 68.06 Million USD | 105.66% |
| Tilray Brands, Inc. | -244.98 Million USD | 98.427% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 132.074% |
| Shineco, Inc. | -22.44 Million USD | 82.837% |
| PetIQ, Inc. | 2.13 Million USD | 280.807% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 10.434% |
| Incannex Healthcare Limited | -18.45 Million USD | 79.127% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 101.543% |
| Alimera Sciences, Inc. | -20.13 Million USD | 80.861% |
| Silver Spike Investment Corp. | 7.34 Million USD | 152.492% |
| Assertio Holdings, Inc. | -331.94 Million USD | 98.839% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 41.557% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 52.8% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | 78.474% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.79% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 97.596% |
| Hempacco Co., Inc. | -13.12 Million USD | 70.646% |
| Talphera, Inc. | -18.39 Million USD | 79.056% |
| Alvotech | -551.73 Million USD | 99.302% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 110.81% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 101.18% |
| Currenc Group, Inc. | -15.3 Million USD | 74.828% |
| Kamada Ltd. | 8.28 Million USD | 146.511% |
| Indivior PLC | 2 Million USD | 292.65% |
| Evoke Pharma, Inc. | -7.79 Million USD | 50.554% |
| Flora Growth Corp. | -57.03 Million USD | 93.245% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 80.79% |
| Evolus, Inc. | -61.68 Million USD | 93.754% |
| HUTCHMED (China) Limited | 100.78 Million USD | 103.823% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 102.801% |
| Akanda Corp. | -32.27 Million USD | 88.062% |